62-year-old Luther Roden is the first in east Texas to benefit from a heart bypass procedure done totally endoscopically using the da Vinci Robotic Surgical System.

Researchers have identified another hunting danger - the hidden danger of a heart attack among men with risk factors and known heart disease.

Synvista Therapeutics announced dosing of the first patient in BENEFICIAL trial, a novel compound designed to act as an AGE-cross-link breaker, in patients with chronic heart failure.

Investigational agent of Astellas Pharma US vernakalant hydrochloride increased conversion to normal heart rhythm in patients with atrial fibrillation.

People with diabetes who have asymptomatic heart disease may be able to vastly improve the flow of blood to their hearts without surgical intervention.

Nile Therapeutics announced results from a Phase 1a clinical study of CD-NP, Nile's selective NPR-B agonist being developed for the treatment of heart failure. The results of this study will be included in the Company's presentation today at the BIO Investor Forum in San Francisco, CA.

American Heart Association's free online grocery list builder to create a heart-healthy shopping list filled with products bearing the heart-check mark.

Older women who experience at least one full-blown panic attack may have an increased risk of having a heart attack or stroke and an increased risk of death in the next five years.

Women and blacks are less likely than white men to receive implantable heart defibrillators.

Many Americans hospitalized for heart failure are coming up short when it comes to getting the therapy they need - especially women and minorities.

HSFC and CIHR launched of a groundbreaking new international study to assess the impact of heart and stroke (cardiovascular) research.

A research is challenging conventional thinking on how the cholesterol-reducing drugs statins benefit heart patients.

Heart patients who most frequently miss a medication dose are more than twice as likely to suffer heart attack, stroke and death.

Global Cardio Care Centers and its board-certified cardiologists and internal medicine physicians deliver pioneering enhanced external counterpulsation, or EECP providing FDA-approved treatment is first and foremost for people with congestive heart failure, coronary artery disease and angina.

A new generation of implanted heart-assisting pump does very well at helping severely ill heart-failure patients survive, and thrive, until they receive a heart transplant.